Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.

Jia Q, Bowen R, Dillon BJ, Masleša-Galić S, Chang BT, Kaidi AC, Horwitz MA.

Sci Rep. 2018 May 3;8(1):7009. doi: 10.1038/s41598-018-24581-y.

2.

Plague Vaccine Development: Current Research and Future Trends.

Verma SK, Tuteja U.

Front Immunol. 2016 Dec 14;7:602. doi: 10.3389/fimmu.2016.00602. eCollection 2016. Review.

3.

Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques.

Zhang Q, Wang Q, Tian G, Qi Z, Zhang X, Wu X, Qiu Y, Bi Y, Yang X, Xin Y, He J, Zhou J, Zeng L, Yang R, Wang X.

Hum Vaccin Immunother. 2014;10(2):368-77. doi: 10.4161/hv.27060. Epub 2013 Nov 13.

4.

Evaluation of YadC protein delivered by live attenuated Salmonella as a vaccine against plague.

Sun W, Olinzock J, Wang S, Sanapala S, Curtiss R 3rd.

Pathog Dis. 2014 Mar;70(2):119-31. doi: 10.1111/2049-632X.12076. Epub 2013 Sep 10.

5.

Acquisition of maternal antibodies both from the placenta and by lactation protects mouse offspring from Yersinia pestis challenge.

Qi Z, Zhao H, Zhang Q, Bi Y, Ren L, Zhang X, Yang H, Yang X, Wang Q, Li C, Zhou J, Xin Y, Yang Y, Yang H, Du Z, Tan Y, Han Y, Song Y, Zhou L, Zhang P, Cui Y, Yan Y, Zhou D, Yang R, Wang X.

Clin Vaccine Immunol. 2012 Nov;19(11):1746-50. doi: 10.1128/CVI.00455-12. Epub 2012 Aug 29.

6.

The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.

Williamson ED.

Adv Prev Med. 2012;2012:365980. doi: 10.1155/2012/365980. Epub 2011 Sep 29.

7.

Developing live vaccines against plague.

Sun W, Roland KL, Curtiss R 3rd.

J Infect Dev Ctries. 2011 Sep 14;5(9):614-27. Review.

8.

Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization.

Zhang H, Liu L, Wen K, Huang J, Geng S, Shen J, Pan Z, Jiao X.

Cell Mol Immunol. 2011 Nov;8(6):496-501. doi: 10.1038/cmi.2011.24. Epub 2011 Aug 15.

9.

Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.

Embry A, Meng X, Cantwell A, Dube PH, Xiang Y.

Vaccine. 2011 Jul 26;29(33):5331-9. doi: 10.1016/j.vaccine.2011.05.088. Epub 2011 Jun 12.

10.

Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.

Brewoo JN, Powell TD, Stinchcomb DT, Osorio JE.

Vaccine. 2010 Aug 16;28(36):5891-9. doi: 10.1016/j.vaccine.2010.06.054. Epub 2010 Jul 12.

11.

Protection against pneumonic plague following oral immunization with a non-replicating vaccine.

Jones A, Bosio C, Duffy A, Goodyear A, Schriefer M, Dow S.

Vaccine. 2010 Aug 16;28(36):5924-9. doi: 10.1016/j.vaccine.2010.06.020. Epub 2010 Jun 19.

12.

Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice.

Wang Z, Zhou L, Qi Z, Zhang Q, Dai R, Yang Y, Cui B, Wang H, Yang R, Wang X.

Clin Vaccine Immunol. 2010 Jan;17(1):199-201. doi: 10.1128/CVI.00305-09. Epub 2009 Nov 25.

13.

Technical transformation of biodefense vaccines.

Lu S, Wang S.

Vaccine. 2009 Nov 5;27 Suppl 4:D8-D15. doi: 10.1016/j.vaccine.2009.08.055. Review.

15.

Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.

Mizel SB, Graff AH, Sriranganathan N, Ervin S, Lees CJ, Lively MO, Hantgan RR, Thomas MJ, Wood J, Bell B.

Clin Vaccine Immunol. 2009 Jan;16(1):21-8. doi: 10.1128/CVI.00333-08. Epub 2008 Nov 5.

16.

Immune defense against pneumonic plague.

Smiley ST.

Immunol Rev. 2008 Oct;225:256-71. doi: 10.1111/j.1600-065X.2008.00674.x. Review.

17.

Current challenges in the development of vaccines for pneumonic plague.

Smiley ST.

Expert Rev Vaccines. 2008 Mar;7(2):209-21. doi: 10.1586/14760584.7.2.209. Review.

18.

Interaction between Yersinia pestis and the host immune system.

Li B, Yang R.

Infect Immun. 2008 May;76(5):1804-11. doi: 10.1128/IAI.01517-07. Epub 2008 Feb 4. Review. No abstract available.

20.

Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, Wang LC, Clark PK, Giardina SL, Adamovicz JJ, Michiel DF.

Protein Expr Purif. 2007 May;53(1):63-79. Epub 2006 Dec 31.

Supplemental Content

Support Center